Synertec named as design lead on ANSTO’s $45.5M nuclear medicine facility
Synertec Corporation has confirmed the client behind its previously announced $45.5M engineering services contract is the Australian Nuclear Science and Technology Organisation (ANSTO). The contract, first disclosed on 7 September 2026, covers an approximately eight-year program at ANSTO’s Lucas Heights campus in New South Wales, where Synertec will serve as Process Design and Design Integration lead under ANSTO’s Nuclear Medicine Manufacturing Program (NMMP). At 2.4 times Synertec Engineering’s External revenue in FY26, the award represents a materially transformative engagement for the company.
Synertec’s FY26 cash turnaround, which delivered the company’s first positive operating cash flow since FY19 and pushed work in hand up 188% to $20.9M, provides the financial baseline against which the ANSTO contract’s 2.4x revenue multiple is measured.
The $45.5M government engineering contract was first disclosed on 7 September 2026 without naming the client, with the award described at the time as capital-light revenue requiring no material project-related capital expenditure and placing FY27 guidance of $29.5M-$31.7M under immediate review.
When big ASX news breaks, our subscribers know first
Project financials that investors need to know
The financial profile of the ANSTO contract carries several metrics of note for investors assessing near-term revenue contribution and cash generation.
| Metric | Detail |
|---|---|
| Total contract value | $45.5M (~8-year program) |
| Revenue in initial 26-month design phase | ~$36M (commencing 21 September 2026) |
| Contribution margin | Expected to exceed 25% |
| Gross margin on labour | Top end of target range |
| Cash flow profile | Expected to be cumulatively cash-flow positive for more than 90% of contract term |
| Working capital requirement | Minimal; serviceable from existing debt facility and recent equity raise |
Synertec continues to assess the impact of the ANSTO contract on its FY27 revenue guidance. As mobilisation activities progress and greater certainty is obtained regarding delivery schedules and revenue recognition milestones, the company expects the contract to have a favourable impact on FY27 revenue relative to previously issued guidance. A further update is expected once sufficient certainty exists regarding the project execution profile. No formal guidance revision has been made at this stage.
What is Australia’s Nuclear Medicine Manufacturing Program?
ANSTO’s Nuclear Medicine Manufacturing Program is a nationally significant infrastructure initiative that underpins Australia’s capacity to produce critical medical products. For investors unfamiliar with the sector, the following points outline what the program involves and why it matters.
- What nuclear medicines do: Nuclear medicines are used in diagnostic imaging and in the treatment of certain cancers. They are time-sensitive, highly regulated products that require specialist manufacturing facilities.
- Why ANSTO is the national provider: ANSTO operates at its Lucas Heights campus in NSW, where it maintains radiopharmaceutical production infrastructure serving the Australian healthcare system and international markets.
- What the new facility replaces: The NMMP will deliver a next-generation Nuclear Medicine Manufacturing Facility to replace ANSTO’s existing radiopharmaceutical production infrastructure, which has been in operation for many years.
- Why sovereign capability matters: Maintaining domestic production of nuclear medicines reduces Australia’s dependence on international supply chains for critical healthcare products, and positions ANSTO’s output to serve both the Australian healthcare system and international markets over the long term.
Synertec’s appointment as Process Design and Design Integration lead places the company at the centre of this program, reinforcing its growing strategic relevance in the healthcare and nuclear sectors.
Strategic positioning and what comes next for Synertec
Validating a deliberate diversification strategy
The ANSTO award further validates Synertec’s deliberate industry diversification and geographic expansion strategy. The contract strengthens the company’s position across the healthcare, nuclear, defence, and critical infrastructure sectors, each representing distinct growth pathways beyond Synertec’s historical base. The project will also accelerate the growth of Synertec’s New South Wales operations, providing a strong platform from which to pursue additional opportunities across the healthcare, nuclear, defence and critical infrastructure sectors.
Scope of work and delivery model
Synertec’s responsibilities across the facility’s design and delivery lifecycle are broad. The scope of work includes:
- Process architecture and engineering design
- Specialised GMP and radiological manufacturing systems and utilities
- Systems engineering, requirements and interface management
- Facility-wide systems integration and procurement and vendor integration support
- Regulatory, licensing, and digital engineering and design assurance services
- Construction, commissioning, qualification, and operational readiness support
Delivery will be through Synertec’s existing specialist engineering capability, supported by targeted recruitment in New South Wales aligned to the project delivery schedule.
MD commentary
Michael Carroll, Managing Director, Synertec Corporation Ltd
“We are delighted to now be able to identify ANSTO as our client and provide further information regarding this nationally significant project. This award reflects Synertec’s capability in highly regulated engineering environments and positions the Company at the centre of one of Australia’s most important healthcare and sovereign capability infrastructure programs.”
The project commences 21 September 2026. Investors should watch for Synertec’s FY27 guidance update as project mobilisation progresses and the company obtains greater certainty around its execution profile and revenue recognition schedule.
Stay Ahead on ASX Healthcare and Engineering News
Get FREE breaking ASX announcements delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who never miss a market-moving update. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment news breaks.